Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048230 · ClinicalTrials.gov registry record · Phase 3
PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 3 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 620
- Enrollment target
NCT00048230 is a Phase 3 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 620 participants.
The verdict
NCT00048230, a Phase 3 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 620 participants
- Enrollment target
Study Summary
This study will compare the efficacy of PS-341 versus high dose dexamethasone.
Interventions
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 620 participants |
| Start Date | 2002-06 |
| Est. Completion | 2004-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00048230
The ClinicalTrials.gov registry entry for NCT00048230 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 620 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bortezomib is the first listed.
NCT00048230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00048230 about?
NCT00048230 is a clinical study titled "PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma". This study will compare the efficacy of PS-341 versus high dose dexamethasone.
What is the current status of trial NCT00048230?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 620 participants. The study started on 2002-06. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00048230?
The interventions under investigation include: bortezomib (DRUG).
Who is sponsoring clinical trial NCT00048230?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.